Delivery Order SPE2DB20D1100-SPE2DB24FC5R4

Award Date 7/2/24
Potential Completion Date 7/24/24
Potential Value $2.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,526.54 firm fixed-price delivery order is for the supply of the pharmaceutical product HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. The contract has an ultimate completion date of April 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,526.54 firm fixed-price delivery order is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a medication. The contract has an ultimate completion date of February 11, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was made to Amerisourcebergen Drug Corp, Corporate Office Division, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,485.20 firm fixed-price delivery order is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a specialty medication. The contract has an ultimate completion date of August 26, 2024. Amerisourcebergen is a significant supplier of pharmaceutical and medical products to various government...
This federal contract award, valued at $3,313.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The award is a firm fixed price delivery order for the medication Hemangeol (4.28 mg/ml oral solution, 120 ml), a specialty pharmaceutical product. AmerisourceBergen Drug Corp serves as a prime contractor providing a wide range of pharmaceutical products and medical supplies...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is for the delivery of Hemangeol 4.28 mg/ml oral solution in 120 ml bottles. The $1,242.60 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 9, 2024. The contract does not have a set-aside designation. As a major pharmaceutical distributor, Amerisourcebergen has been awarded numerous indefinite delivery contracts...
This federal contract award, valued at $28,113.75, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract is a Delivery Order placed under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA, which has a ceiling value of up to $999,999,999.00 through December 31, 2025. This single-award IDC...
This federal contract award is for a delivery order valued at $23,753.10, awarded to Amerisourcebergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is a firm fixed price arrangement to provide pharmaceutical products and medical supplies to the DLA. Amerisourcebergen, a major pharmaceutical distribution company, holds a single-award Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00...
This federal contract award, valued at $14,277.00, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The award is a Delivery Order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
The U.S. government agency the Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,015.56 delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is a firm fixed-price agreement for the delivery of pharmaceutical products and medical supplies. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the...
This federal contract award, valued at $56,373.72, was made to Amerisourcebergen Drug Corp's Corporate Office division, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the Defense Logistics Agency (DLA) Troop Support Medical, which has a potential value of up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB24FC5R4
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp's Corporate Office Division. The $2,485.20 firm fixed price delivery order is for the supply of the pharmaceutical product HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation.

Generated 10/1/24, 10:45 AM